用于阿尔茨海默病治疗和诊断的肽。
Peptides for therapy and diagnosis of Alzheimer's disease.
机构信息
Forschungszentrum Julich, ICS-6, D-52425 Julich, Germany.
出版信息
Curr Pharm Des. 2012;18(6):755-67. doi: 10.2174/138161212799277752.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis "probable AD" can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-βpeptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβ play a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.
摘要
阿尔茨海默病（AD）是一种进行性神经退行性疾病，具有破坏性影响。发生 AD 的最大危险因素是年龄。如今，只有对症治疗方法可用。此外，AD 只能在死后才能确定诊断，而只有当出现严重的临床症状时，才能最早确定“可能的 AD”诊断。神经原纤维缠结和淀粉样斑块等特定的神经病理学变化定义了 AD。淀粉样斑块主要由淀粉样-β肽（Aβ）组成。有几条证据表明，Aβ 的浓度逐渐增加，随后聚集和积累，在疾病进展中起基础性作用。因此，与 Aβ结合并影响其聚集的物质具有重要意义。有大量用于治疗目的的有机物质被描述。这篇综述专注于为 AD 的诊断和治疗而开发的肽，并讨论了肽类药物的优缺点。
相似文献
1
Peptides for therapy and diagnosis of Alzheimer's disease.用于阿尔茨海默病治疗和诊断的肽。
Curr Pharm Des. 2012;18(6):755-67. doi: 10.2174/138161212799277752.
2
A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies.在阿尔茨海默病啮齿动物模型或人类临床研究中具有有效治疗潜力的肽的调查。
Mini Rev Med Chem. 2012 May;12(5):388-98. doi: 10.2174/138955712800493942.
3
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
4
[Alzheimer disease: cellular and molecular aspects].[阿尔茨海默病：细胞与分子层面]
Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1.
5
Alzheimer's disease amyloid-β pathology in the lens of the eye.阿尔茨海默病淀粉样β病理在眼睛的晶状体中。
Exp Eye Res. 2022 Aug;221:108974. doi: 10.1016/j.exer.2022.108974. Epub 2022 Feb 21.
6
The YENPTY motif of APP: Progress and insights toward a targeted therapy for Alzheimer's disease patients.淀粉样前体蛋白（APP）的 YENPTY 基序：针对阿尔茨海默病患者的靶向治疗的进展和研究进展。
Ageing Res Rev. 2019 Jul;52:120-128. doi: 10.1016/j.arr.2019.04.003. Epub 2019 Apr 27.
7
Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.阿尔茨海默病中斑块形成及β-淀粉样蛋白在神经元内的积聚。
Pathol Int. 2017 Apr;67(4):185-193. doi: 10.1111/pin.12520. Epub 2017 Mar 5.
8
Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches.阿尔茨海默病：蛋白质在发病机制、作用机制和新治疗方法中的作用。
Neurosci Lett. 2023 Nov 20;817:137532. doi: 10.1016/j.neulet.2023.137532. Epub 2023 Oct 20.
9
Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.肽、拟肽和糖肽-肽缀合物作为阿尔茨海默病淀粉样蛋白聚集抑制剂。
ACS Chem Neurosci. 2018 Jul 18;9(7):1530-1551. doi: 10.1021/acschemneuro.8b00185. Epub 2018 Jun 26.
10
[Recent progress in the development of disease-modifying therapies for Alzheimer's disease].[阿尔茨海默病疾病修饰疗法的研发进展]
Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Feb;30(1):1-8.
引用本文的文献
1
Structural Analysis of Amylin and Amyloid β Peptide Signaling in Alzheimer's Disease.阿尔茨海默病中胰淀素与β淀粉样肽信号传导的结构分析
Biomolecules. 2025 Jan 9;15(1):89. doi: 10.3390/biom15010089.
2
Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1-42).五肽对淀粉样β肽（1-42）聚合及细胞毒性抑制作用的分子整合研究
Curr Issues Mol Biol. 2024 Sep 14;46(9):10160-10179. doi: 10.3390/cimb46090606.
3
Aggregation Limiting Cell-Penetrating Peptides Derived from Protein Signal Sequences.蛋白信号序列衍生的聚集限制穿膜肽。
Int J Mol Sci. 2023 Feb 21;24(5):4277. doi: 10.3390/ijms24054277.
4
A cationic amphiphilic peptide chaperone rescues Aβ aggregation and cytotoxicity.一种阳离子两亲性肽伴侣可挽救Aβ聚集和细胞毒性。
RSC Med Chem. 2022 Dec 10;14(2):332-340. doi: 10.1039/d2md00414c. eCollection 2023 Feb 22.
5
The Real-Time Validation of the Effectiveness of Third-Generation Hyperbranched Poly(ɛ-lysine) Dendrons-Modified KLVFF Sequences to Bind Amyloid-β Peptides Using an Optical Waveguide Light-Mode Spectroscopy System.第三代超支化聚（ε-赖氨酸）树枝状聚合物修饰的 KLVFF 序列通过光波导光模式光谱系统结合淀粉样β肽的实时有效性验证。
Sensors (Basel). 2022 Dec 6;22(23):9561. doi: 10.3390/s22239561.
6
TRPV1 Modulator Ameliorates Alzheimer-Like Amyloid- Neuropathology via Akt/Gsk3-Mediated Nrf2 Activation in the Neuro-2a/APP Cell Model.TRPV1 调节剂通过 Akt/Gsk3 介导的 Nrf2 激活改善神经 2a/APP 细胞模型中的阿尔茨海默样淀粉样神经病理学。
Oxid Med Cell Longev. 2022 Aug 27;2022:1544244. doi: 10.1155/2022/1544244. eCollection 2022.
7
Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease?β淀粉样蛋白和 Tau 与金属离子、脂膜和基于肽的淀粉样蛋白抑制剂相互作用：这些共同特征在阿尔茨海默病中是否相关？
Molecules. 2022 Aug 9;27(16):5066. doi: 10.3390/molecules27165066.
8
Copper chelating cyclic peptidomimetic inhibits Aβ fibrillogenesis.铜螯合环肽模拟物抑制淀粉样β蛋白原纤维形成。
RSC Med Chem. 2022 May 9;13(6):761-774. doi: 10.1039/d2md00019a. eCollection 2022 Jun 22.
9
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.tau 聚集抑制肽作为阿尔茨海默病的潜在治疗方法。
Cell Mol Neurobiol. 2023 Apr;43(3):951-961. doi: 10.1007/s10571-022-01230-7. Epub 2022 May 21.
10
Effect of C-terminus amidation of Aβ fragment derived peptides as potential inhibitors of Aβ aggregation.Aβ片段衍生肽的C末端酰胺化作为Aβ聚集潜在抑制剂的作用。
RSC Adv. 2020 Jul 21;10(45):27137-27151. doi: 10.1039/d0ra04788k. eCollection 2020 Jul 15.
本文引用的文献
1
Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.口服 D 型氨基酸 D3 改善阿尔茨海默病转基因小鼠的病理和行为。
ACS Chem Neurosci. 2010 Sep 15;1(9):639-48. doi: 10.1021/cn100057j. Epub 2010 Aug 2.
2
Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.用于阿尔茨海默病淀粉样斑块分子靶向的 6 肽淀粉样β蛋白衍生噬菌体展示文库的设计与评价：与源自随机噬菌体展示文库的两个环状七肽的比较。
Peptides. 2011 Jun;32(6):1232-43. doi: 10.1016/j.peptides.2011.04.026. Epub 2011 May 6.
3
Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.作为治疗神经退行性 tau 病的一种治疗策略，调节蛋白质-蛋白质相互作用。
Curr Top Med Chem. 2011;11(3):317-30. doi: 10.2174/156802611794072605.
4
Selection of peptide inhibitors of soluble Aβ(1-42) oligomer formation by phage display.通过噬菌体展示筛选可溶性Aβ(1-42)寡聚体形成的肽抑制剂。
Biosci Biotechnol Biochem. 2010;74(11):2214-9. doi: 10.1271/bbb.100388. Epub 2010 Nov 7.
5
Combining independent drug classes into superior, synergistically acting hybrid molecules.将独立的药物类别组合成更高级的、具有协同作用的混合分子。
Angew Chem Int Ed Engl. 2010 Nov 8;49(46):8743-6. doi: 10.1002/anie.201004437.
6
Tau pathology and future therapeutics.tau 病理学与未来治疗策略
Curr Alzheimer Res. 2010 Dec;7(8):685-96. doi: 10.2174/156720510793611628.
7
Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.反义肽作为阿尔茨海默病β-淀粉样蛋白聚集抑制剂的研发。
Peptides. 2010 Oct;31(10):1866-72. doi: 10.1016/j.peptides.2010.06.033. Epub 2010 Jul 13.
8
EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.EGCG 重塑成熟的 α-突触核蛋白和淀粉样-β 纤维，并降低细胞毒性。
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7710-5. doi: 10.1073/pnas.0910723107. Epub 2010 Apr 12.
9
Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.开发一种蛋白水解稳定的β-淀粉样寡聚体反向肽抑制剂作为治疗阿尔茨海默病的潜在新型药物。
Biochemistry. 2010 Apr 20;49(15):3261-72. doi: 10.1021/bi100144m.
10
Amyloid imaging in early detection of Alzheimer's disease.淀粉样蛋白成像在阿尔茨海默病的早期检测中的应用。
Neurodegener Dis. 2010;7(1-3):136-8. doi: 10.1159/000289223. Epub 2010 Mar 3.
Zotero 插件